Regeneron Pharmaceuticals spent over *** billion U.S. dollars on research and development in 2024, up from *** billion U.S. dollars in the preceding year. The statistic illustrates the annual research and development expenses for Regeneron Pharmaceuticals between 2016 and 2024. Regeneron is a U.S-based global biotech company with headquarters in Tarrytown, New York.

Regeneron Pharmaceuticals reported $530.2M in Cost of Sales for its fiscal quarter ending in June of 2025. Data for Regeneron Pharmaceuticals | REGN - Cost Of Sales including historical, tables and charts were last updated by Trading Economics this last August in 2025.

Regeneron is a U.S-based global biotech company with headquarters in Tarrytown, New York. The statistic illustrates the operating expenses of Regeneron Pharmaceuticals from 2018 to 2024. In 2024, operating expenses for Regeneron amounted to 10.2 billion U.S. dollars.

Regeneron Pharmaceuticals reported $2.6B in Operating Expenses for its fiscal quarter ending in June of 2025. Data for Regeneron Pharmaceuticals | REGN - Operating Expenses including historical, tables and charts were last updated by Trading Economics this last August in 2025.

Regeneron Pharmaceuticals sg&a expenses for the twelve months ending March 31, 2025 were $2.898B, a 6.59% increase year-over-year. Regeneron Pharmaceuticals annual sg&a expenses for 2024 were $2.954B, a 12.28% increase from 2023. Regeneron Pharmaceuticals annual sg&a expenses for 2023 were $2.631B, a 24.36% increase from 2022. Regeneron Pharmaceuticals annual sg&a expenses for 2022 were $2.116B, a 15.95% increase from 2021.

Regeneron Pharmaceuticals reported $634.2M in Selling and Administration Expenses for its fiscal quarter ending in June of 2025. Data for Regeneron Pharmaceuticals | REGN - Selling And Administration Expenses including historical, tables and charts were last updated by Trading Economics this last August in 2025.

Regeneron Pharmaceuticals reported 13.35 in PE Price to Earnings for its fiscal quarter ending in June of 2025. Data for Regeneron Pharmaceuticals | REGN - PE Price to Earnings including historical, tables and charts were last updated by Trading Economics this last August in 2025.

Regeneron Pharmaceuticals, Inc. (REGN) stock price today 580.37 USD with a 24-hour change of 2.54%. View real-time Regeneron Pharmaceuticals, Inc. stock chart, news, statistics, and key fundamentals.

Regeneron Pharmaceuticals stock price, live market quote, shares value, historical data, intraday chart, earnings per share and news.

This analysis presents a rigorous exploration of financial data, incorporating a diverse range of statistical features. By providing a robust foundation, it facilitates advanced research and innovative modeling techniques within the field of finance.

Regeneron Stock Forecast & Analysis

Financial data:

• Historical daily stock prices (open, high, low, close, volume)

• Fundamental data (e.g., market capitalization, price to earnings P/E ratio, dividend yield, earnings per share EPS, price to earnings growth, debt-to-equity ratio, price-to-book ratio, current ratio, free cash flow, projected earnings growth, return on equity, dividend payout ratio, price to sales ratio, credit rating)

• Technical indicators (e.g., moving averages, RSI, MACD, average directional index, aroon oscillator, stochastic oscillator, on-balance volume, accumulation/distribution A/D line, parabolic SAR indicator, bollinger bands indicators, fibonacci, williams percent range, commodity channel index)

Machine learning features:

• Feature engineering based on financial data and technical indicators

• Sentiment analysis data from social media and news articles

• Macroeconomic data (e.g., GDP, unemployment rate, interest rates, consumer spending, building permits, consumer confidence, inflation, producer price index, money supply, home sales, retail sales, bond yields)

Potential Applications:

• Stock price prediction

• Portfolio optimization

• Algorithmic trading

• Market sentiment analysis

• Risk management

Use Cases:

• Researchers investigating the effectiveness of machine learning in stock market prediction

• Analysts developing quantitative trading Buy/Sell strategies

• Individuals interested in building their own stock market prediction models

• Students learning about machine learning and financial applications

Additional Notes:

• The dataset may include different levels of granularity (e.g., daily, hourly)

• Data cleaning and preprocessing are essential before model training

• Regular updates are recommended to maintain the accuracy and relevance of the data

Regeneron Pharmaceuticals reported $3.6M in Interest Expense on Debt for its fiscal quarter ending in June of 2025. Data for Regeneron Pharmaceuticals | REGN - Interest Expense On Debt including historical, tables and charts were last updated by Trading Economics this last August in 2025.

This analysis presents a rigorous exploration of financial data, incorporating a diverse range of statistical features. By providing a robust foundation, it facilitates advanced research and innovative modeling techniques within the field of finance.

Regeneron's (REGN) Eye on the Prize: Will Growth Sustain or Will the Market Dim the Vision?

Financial data:

• Historical daily stock prices (open, high, low, close, volume)

• Fundamental data (e.g., market capitalization, price to earnings P/E ratio, dividend yield, earnings per share EPS, price to earnings growth, debt-to-equity ratio, price-to-book ratio, current ratio, free cash flow, projected earnings growth, return on equity, dividend payout ratio, price to sales ratio, credit rating)

• Technical indicators (e.g., moving averages, RSI, MACD, average directional index, aroon oscillator, stochastic oscillator, on-balance volume, accumulation/distribution A/D line, parabolic SAR indicator, bollinger bands indicators, fibonacci, williams percent range, commodity channel index)

Machine learning features:

• Feature engineering based on financial data and technical indicators

• Sentiment analysis data from social media and news articles

• Macroeconomic data (e.g., GDP, unemployment rate, interest rates, consumer spending, building permits, consumer confidence, inflation, producer price index, money supply, home sales, retail sales, bond yields)

Potential Applications:

• Stock price prediction

• Portfolio optimization

• Algorithmic trading

• Market sentiment analysis

• Risk management

Use Cases:

• Researchers investigating the effectiveness of machine learning in stock market prediction

• Analysts developing quantitative trading Buy/Sell strategies

• Individuals interested in building their own stock market prediction models

• Students learning about machine learning and financial applications

Additional Notes:

• The dataset may include different levels of granularity (e.g., daily, hourly)

• Data cleaning and preprocessing are essential before model training

• Regular updates are recommended to maintain the accuracy and relevance of the data

View Regeneron Pharmaceuticals Inc's historical fixed income issuance and pricing profile here.

The Interleukin Inhibitors market for Rheumatoid Arthritis (RA) is experiencing robust growth, driven by the increasing prevalence of RA globally and the limitations of existing therapies. The market, estimated at $5 billion in 2025, is projected to achieve a Compound Annual Growth Rate (CAGR) of 8% between 2025 and 2033, reaching approximately $9 billion by 2033. This growth is fueled by several factors, including the approval of novel interleukin inhibitors with improved efficacy and safety profiles, the rising awareness of targeted therapies for RA, and an aging global population experiencing higher rates of autoimmune diseases. The market is segmented by drug type (e.g., anti-IL-6, anti-IL-17), route of administration, and geography. Key players like Sanofi, Regeneron Pharmaceuticals, Roche, and Biogen are driving innovation through research and development, leading to a competitive landscape marked by both established and emerging therapies. Despite the significant market potential, challenges remain. High drug costs and potential side effects associated with interleukin inhibitors continue to limit market penetration. Additionally, the development of biosimilars poses a threat to the profitability of originator drugs in the coming years. The market's regional landscape shows significant variations in growth rates, with North America and Europe holding the largest market shares due to high healthcare expenditure and greater access to advanced therapies. However, the emerging markets of Asia-Pacific are projected to witness rapid growth in the forecast period, driven by increasing disposable income and rising healthcare awareness. Continued research and development focusing on improved safety profiles, targeted delivery systems, and cost-effective solutions will be essential to unlocking the full potential of this market.

Regeneron Pharmaceuticals reported $1.66B in EBITDA for its fiscal quarter ending in June of 2025. Data for Regeneron Pharmaceuticals | REGN - Ebitda including historical, tables and charts were last updated by Trading Economics this last August in 2025.

The global market for cholesterol-lowering biologic drugs is experiencing robust growth, driven by increasing prevalence of cardiovascular diseases, rising awareness of lipid management, and advancements in therapeutic approaches. The market size in 2025 is estimated at $15 billion, exhibiting a Compound Annual Growth Rate (CAGR) of 8% from 2025 to 2033. This significant growth is fueled by several key factors. Firstly, the aging global population is leading to a higher incidence of hyperlipidemia, a major risk factor for cardiovascular diseases. Secondly, the development of novel biologic therapies, such as PCSK9 inhibitors and other emerging modalities, offers improved efficacy and safety profiles compared to traditional statins, driving market expansion. Thirdly, increasing healthcare expenditure and improved access to advanced therapies in developing economies are contributing to market growth. However, high treatment costs and potential side effects associated with some biologic drugs pose challenges to market penetration. Furthermore, the market is segmented based on drug type (PCSK9 inhibitors, etc.), administration route, and geography. Despite these challenges, the forecast suggests continued market expansion, reaching an estimated $26 billion by 2033. Key players such as Amgen, Regeneron Pharmaceuticals, and Alnylam Pharmaceuticals are actively involved in research and development, focusing on enhancing efficacy, optimizing safety profiles, and expanding their product portfolios. Competition amongst these companies is driving innovation and further shaping the market landscape. The geographical segmentation shows a significant market share held by North America and Europe, primarily driven by high healthcare spending, advanced healthcare infrastructure and strong regulatory frameworks. Emerging markets are expected to witness significant growth in the coming years, driven by increasing healthcare awareness and accessibility.

Historical price series and percentage performance for REGN across multiple ranges.

The PCSK9 inhibitor market, encompassing drugs targeting PCSK9 proteins to lower LDL cholesterol, is poised for significant growth. While precise market figures are unavailable, based on the provided information and industry analysis, we can project robust expansion. The market's expansion is driven by the increasing prevalence of cardiovascular diseases, particularly high cholesterol, a major risk factor for heart attacks and strokes. The rising geriatric population, coupled with increasing awareness about preventative healthcare and the efficacy of PCSK9 inhibitors, further fuels market growth. These drugs offer substantial benefits to patients with high cholesterol who don't respond adequately to statins or have genetic predispositions. Key players like Regeneron Pharmaceuticals, Sanofi, Novartis, Innovent Biologics, and Amgen are actively involved in research, development, and marketing efforts, contributing to market dynamism. However, factors like high drug costs, potential side effects, and the need for ongoing administration present challenges to wider market adoption. Despite these challenges, the projected Compound Annual Growth Rate (CAGR) indicates a sustained upward trajectory. Technological advancements are continuously improving the efficacy and safety profiles of PCSK9 inhibitors, potentially mitigating some of the existing restraints. The market is segmented by various factors, including drug type, route of administration, and geography. North America and Europe currently dominate the market due to higher healthcare expenditure and advanced healthcare infrastructure. However, emerging markets in Asia-Pacific are expected to witness rapid growth in the coming years driven by rising disposable income and increasing awareness of cardiovascular health. Future growth will depend on further clinical trials confirming long-term efficacy and safety, as well as the development of more cost-effective treatment options and broader insurance coverage.

The global market for medicines treating eosinophilic asthma is experiencing robust growth, driven by increasing prevalence of the disease, advancements in targeted therapies, and a heightened awareness among both patients and healthcare professionals. The market, estimated at $2.5 billion in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of approximately 8% from 2025 to 2033, reaching an estimated market value exceeding $4.5 billion by 2033. This growth is fueled by several key factors: the rising incidence of asthma globally, particularly eosinophilic asthma, which is a more severe form requiring specialized treatment; the development and launch of novel biologics and biosimilars offering improved efficacy and safety profiles compared to traditional therapies; and increased investment in research and development aimed at further refining treatment strategies and identifying new drug targets. The market's segmentation reveals a significant portion attributed to biologics, reflecting the shift towards targeted therapies. Geographically, North America currently holds a substantial market share, driven by high healthcare expenditure and a relatively higher prevalence of eosinophilic asthma. However, Asia Pacific is expected to witness significant growth in the forecast period, propelled by expanding healthcare infrastructure and rising disposable incomes. Major pharmaceutical companies like AstraZeneca, GSK, Regeneron Pharmaceuticals, Sanofi, and Novartis play a pivotal role in shaping the market landscape through their research, development, and commercialization of eosinophilic asthma treatments. Competition among these companies is intense, driving innovation and potentially leading to more affordable and accessible therapies in the future. While the market faces some constraints, such as high treatment costs and potential side effects associated with some biologics, the overall outlook remains positive, promising substantial growth and improved patient outcomes in the coming years. The increasing availability of generic alternatives and the continuous development of innovative therapies will help to reduce costs and broaden access. This will further contribute to the expansion of the eosinophilic asthma treatment market.

Regeneron Pharmaceuticals' Q1 earnings fall short of expectations amid declining Eylea sales, facing competition and pricing challenges.